Your Location: Investor Relations > Investor Relationship Overview > Board of Directors
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
  Board of Directors  
Board of Directors | Management
Simin Zhang

Simin Zhang is our founder and has served as chairman of our board of directors since June 1995. Dr. Zhang is also the chairman of the board of directors of the Neptunus Group. Prior to founding the Neptunus Group in July 1989, he was an employee in CITIC Group from 1986 to 1989. From 1983 to 1986, he was an employee in the PRC Space Administration. He is currently a guest professor at the Harbin Institute of Technology and Jilin University, an executive director of China Enterprise Confederation and China Enterprise Directors Association and the president of Shenzhen General Chamber of Commerce. Dr. Zhang received a bachelor's degree in precision instruments from Harbin Institute of Technology in 1983, an honorary doctorate from University of New Castle in Australia in 1997 and a Ph.D. degree in economics from Nan Kai University in 2001.

Barry J. Buttifant

Barry J. Buttifant has been a director of our company since November 2007. He is a member of our audit committee, compensation committee, corporate governance and nominating committee. He is an independent non-executive director of Daiwa Associate Holdings Limited and Giordano International Limited, and a non-executive director of Synergis Holdings Limited ('Synergis'), all of which are publicly listed companies in Hong Kong. Mr. Buttifant also serves as a non-executive director of Global-Tech Advanced Innovations Inc., a NASDAQ listed company. Mr. Buttifant is currently an executive director of Hsin Chong Construction Group Ltd ('HCCG'). Prior to that, he was group chief executive officer of IDT International Limited. In October 2009, Mr. Buttifant rejoined Mission Hills Group, or MHG, as a Director — Corporate Finance, and prior to this appointment, he had been a consultant to the MHG since December 2008.

Prior to joining MHG, he served as a Principal to KLC Kennic Lui & Company, or KLC, a professional accounting firm and Managing Director of KLC Transactions Limited. Prior joining KLC, Mr. Buttifant was the Executive Director — Finance of the MHG from February 2008 till November 2008. Since December 2004, he was the managing director of Hsin Chong International Holdings Limited, a controlling shareholder of HCCG (which was acquired by MHG in November 2007) and Synergis (which was acquired by HCCG in September 2008). Mr. Buttifant was also an alternate director to both HCCG and Synergis.

Mr. Buttifant was an operating partner of Barings Private Equity Asia Limited. He was also the managing director of Wo Kee Hong (Holdings) Limited, or WKH, from 2001 to 2002 and was the advisor to the board of directors of WKH from November 2002 to April 2004. Prior to joining WKH, he was the managing director of IDT International Limited for over eight years and had worked for Polly Peck Group and Sime Darby Hong Kong Limited for more than 11 years in the capacity of finance director and managing director. Mr. Buttifant is a fellow member of the Association of Chartered Certified Accountants; the Hong Kong Institute of Certified Public Accountants; the Chartered Management Institute; the Hong Kong Management Association; and the Hong Kong Institute of Directors.

Alistair Eric MacCallum Laband

Alistair Eric MacCallum Laband has been a director of our company since November 2007. Mr. Laband is a member of our audit committee, our compensation committee and corporate governance and nominating committee. From November 2008 until the end of March 2011 Mr. Laband was a financial consultant to CITIC Pacific Ltd., a company listed on the Hong Kong Stock Exchange. From 2003 to June 2007, he was a partner of PricewaterhouseCoopers, or PwC, Hong Kong/China and until March 2007, secretary of the PwC Asia Region Board. From 2001 to 2002, he was a partner in charge of the Company Secretarial Services Group of PwC’s Hong Kong office. From 1997 to 2001, he was finance/operations partner and a management board member of the Hong Kong office of Price Waterhouse, or PW, and subsequently, the Hong Kong office of PwC. From 1997 to 1998, he was also in charge of the company secretarial and legal services group of PW’s Hong Kong office. Mr. Laband obtained a bachelor’s degree in law from the University of Cambridge in 1973 and a diploma in accountancy from the University of Strathclyde in 1976. Mr. Laband is a Chartered Accountant of the Institute of Chartered Accountants of Scotland and a Fellow of the Institute of Certified Public Accountants of Hong Kong.

Alan Au

Alan Au has been a director of our company since May 2013. Mr. Au is a member of our audit committee and our compensation committee. Mr. Au currently serves on the assessment panel of the Small Entrepreneur Research Assistance Program (SERAP) of the Hong Kong SAR Government. He is an independent non-executive director and chairman of the audit committee of Simcere Pharmaceutical Group (NYSE: SCR). Mr. Au was the head of Asia healthcare investment banking group for Deutsche Bank AG from 2011 to 2012. Prior to that, he was a director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2011, and a director at Morningside Group responsible for healthcare investments in Asia from 2000 to 2005. From 1995 to 1999, Mr. Au worked at KPMG and KPMG Corporate Finance Ltd., responsible for regional M&A transactions and financial advisory services.

Mr. Au is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst (CFA) designation. He is an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants. Mr. Au received his Bachelor's degree in Psychology from the Chinese University of Hong Kong in 1995, and a Master's degree in Management from Columbia Business School in New York in 2007.

Henry Lu

Henry Lu has been a director of our company since June 2014. Dr. Lu has been Director of Capital Eagle Global Limited since May 2014 and Managing Director of China Merchants Capital since February 2014. Dr. Lu was Partner of SVC China from 2012 to 2014 and Chief Representative of William Blair & Company, L.L.C., Shanghai Representative Office from 2006 to 2011. Prior to that, Dr. Lu was with McKinsey & Company advising global and domestic companies on their growth and financial strategies. Dr. Lu received a PhD from Columbia University in 1997 and an MBA from University of Chicago Business School in 2000.

Rebecca Yingnan Zhang

Ms. Rebecca Yingnan Zhang has been a director of our company since May 2015. Ms. Zhang has been appointed as Chief Executive Officer by the Company's board of directors, effective May 22, 2015. Meanwhile, Ms. Zhang resigned from the position as Chief Operating Officer. Ms. Zhang has over 20 years of experience in the pharmaceutical industry and joined Nepstar in March 1999. She served as executive vice president in charge of procurement, merchandising, logistics and quality departments starting from April 2014. She was the Company’s vice president of procurement and merchandising from January 2009 to April 2014. Prior to that Ms. Zhang served as head of procurement department. Ms. Zhang received a bachelor’s degree in microbiological pharmaceuticals in 1991 from Shenyang Pharmaceutical University.

  China Nepstar Chain Drugstore Ltd.    All Rights Reserved   |   粤ICP备09124876号